New office opens in China


Colin Kerr
Published: Friday, November 1, 2019
EyeKor, Inc., an imaging and data management company for the ophthalmic pharmaceutical clinical trial and ocular preclinical laboratory industries, has announced that it is opening a new office in China to enhance its capability to provide local support for clinical trial sponsors and sites in China and the APAC region.
“Over the past few years, EyeKor has actively collaborated with partners in China, building successful relationships with sponsors, hospitals, academia, reading centres and trial sites. With this new office, EyeKor aims to build upon these partnerships as an imaging contract research organisation (CRO), providing focused support for ophthalmic clinical trials and vision science endeavours in China and the APAC region,” said an EyeKor spokesperson.
“EyeKor is proud to contribute to this momentous trend in China’s drug development paradigms. Establishing a team of imaging trial professionals who are well versed on international regulatory standards, EyeKor is positioned to assist sponsors in China in developing new and urgently needed therapies, particularly for patients suffering from ophthalmic diseases that currently lack approved effective treatments,” said the spokesperson.
EyeKor is dedicated to delivering excellence in data management and analysis services for clinical and preclinical studies and strives to provide added value to clinical trial projects through superior quality, services and deep scientific expertise.
EXCELSIOR is a unique data/imaging management platform offering from EyeKor and is an FDA 510(k)-cleared Class II medical device and compliant with HIPAA, 21 CFR Part 11 and other regulatory requirements.
https://www.eyekor.com/
Tags: EyeKor
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.